Aqsa Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aqsa Khan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Olufunmilola Adeleye
Mayo Clinic Alix School of Medicine, Scottsdale, USA
2 shared publications Alexandra Carolan
Mayo Clinic
1 shared publication- Alexandra Chavez
Mayo Clinic Arizona, Phoenix, USA
1 shared publication Annetta M. Madsen
Mayo Clinic Department of OB/Gyn Division of Urogynecology Rochester Minnesota USA
1 shared publication- Benjamin L. Wright
Division of Allergy, Asthma, and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, United States; Division of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, AZ, United States
1 shared publication - Benjamin M. Brucker
NYU Langone Health, 222 E 41st St 11th Floor, New York, NY, 10017, USA
1 shared publication
Latest Publications
- 1 September 2026
- Published by Wiley in Neurourology and Urodynamics
Real‐World Results of Urethral Bulking With Polyacrylamide Hydrogel Versus Legacy Injectables: A Retrospective Study
Aims: Urethral bulking agents are established minimally invasive treatments for stress urinary incontinence (SUI), though efficacy varies among available materials. Comparative evidence on contemporary bulking agents, particularly polyacrylamide hydrogel (PAHG), remain limited. This study aimed to compare retreatment rates following primary periurethral bulking with PAHG versus other FDA‐approved agents. Methods: We performed a multicenter retrospective cohort study of women undergoing primary periurethral bulking for SUI or stress‐predominant mixed urinary incontinence between 2011 and 2024. Only current FDA‐approved bulking agents were included. The primary outcome was retreatment, defined as any subsequent anti‐incontinence procedure, including repeat bulking injections. Retreatment rates were estimated using Kaplan–Meier methods, with comparisons between PAHG and other agents, as well as between index and non‐index patients treated with PAHG. Cox proportional hazards models assessed predictors of retreatment. Results: Among 623 women undergoing periurethral bulking, 268 (43.0%) received PAHG, 332 (53.3%) calcium hydroxyapatite, 12 (1.9%) polydimethylsiloxane, and 11 (1.8%) carbon‐coated zirconium oxide. The median follow‐up was 2.2 years (IQR 0.9–6.6). Overall, 223 patients (36.6%) underwent retreatment at 2 years (80.7% with repeat bulking, 11.2% with urethral sling placement, and 8.1% underwent both repeat bulking and urethral sling placement). Bulking injection with PAHG was associated with lower retreatment rates compared with other agents (1‐year: 16.5% vs 34.8%; 2‐year: 24.4% vs 44.3%; p < 0.001). After adjusting for comorbidities and procedural factors, PAHG use remained independently associated with a reduced risk of retreatment (HR: 0.53, 95% CI: 0.38–0.75; p < 0.001) as did concomitant prolapse surgery (HR: 0.40, 95% CI: 0.22–0.72; p < 0.001). Retreatment rates following PAHG injection did not differ between index and non‐index patients ( p = 0.73). Conclusions: In this large multicenter cohort, PAHG was associated with significantly lower two‐year retreatment rates compared with other FDA‐approved bulking agents, with consistent effectiveness across index and non‐index patients. PAHG may represent a more durable bulking option than legacy agents for the treatment of SUI in real‐world practice, though long‐term data remains limited.
- 1 September 2026
- Published by Wiley in Neurourology and Urodynamics
Real‐World Results of Urethral Bulking With Polyacrylamide Hydrogel Versus Legacy Injectables: A Retrospective Study
Aims: Urethral bulking agents are established minimally invasive treatments for stress urinary incontinence (SUI), though efficacy varies among available materials. Comparative evidence on contemporary bulking agents, particularly polyacrylamide hydrogel (PAHG), remain limited. This study aimed to compare retreatment rates following primary periurethral bulking with PAHG versus other FDA‐approved agents. Methods: We performed a multicenter retrospective cohort study of women undergoing primary periurethral bulking for SUI or stress‐predominant mixed urinary incontinence between 2011 and 2024. Only current FDA‐approved bulking agents were included. The primary outcome was retreatment, defined as any subsequent anti‐incontinence procedure, including repeat bulking injections. Retreatment rates were estimated using Kaplan–Meier methods, with comparisons between PAHG and other agents, as well as between index and non‐index patients treated with PAHG. Cox proportional hazards models assessed predictors of retreatment. Results: Among 623 women undergoing periurethral bulking, 268 (43.0%) received PAHG, 332 (53.3%) calcium hydroxyapatite, 12 (1.9%) polydimethylsiloxane, and 11 (1.8%) carbon‐coated zirconium oxide. The median follow‐up was 2.2 years (IQR 0.9–6.6). Overall, 223 patients (36.6%) underwent retreatment at 2 years (80.7% with repeat bulking, 11.2% with urethral sling placement, and 8.1% underwent both repeat bulking and urethral sling placement). Bulking injection with PAHG was associated with lower retreatment rates compared with other agents (1‐year: 16.5% vs 34.8%; 2‐year: 24.4% vs 44.3%; p < 0.001). After adjusting for comorbidities and procedural factors, PAHG use remained independently associated with a reduced risk of retreatment (HR: 0.53, 95% CI: 0.38–0.75; p < 0.001) as did concomitant prolapse surgery (HR: 0.40, 95% CI: 0.22–0.72; p < 0.001). Retreatment rates following PAHG injection did not differ between index and non‐index patients ( p = 0.73). Conclusions: In this large multicenter cohort, PAHG was associated with significantly lower two‐year retreatment rates compared with other FDA‐approved bulking agents, with consistent effectiveness across index and non‐index patients. PAHG may represent a more durable bulking option than legacy agents for the treatment of SUI in real‐world practice, though long‐term data remains limited.
- Open Access
- 11 December 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Exploring the prevalence of urinary incontinence in multi-ethnic refugee women in Maricopa county, Arizona
This study explores the prevalence of urinary incontinence among multi-ethnic refugee women and their comfort levels in discussing this topic with their he
- 11 December 2025
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessExploring the prevalence of urinary incontinence in multi-ethnic refugee women in Maricopa county, Arizona
This study explores the prevalence of urinary incontinence among multi-ethnic refugee women and their comfort levels in discussing this topic with their he
- 26 November 2025
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 20 (1) , 20
The Impact of Genital Hiatus in the Long-term Outcomes of Apical Prolapse Repair
- 26 November 2025
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 20 (1) , 20
The Impact of Genital Hiatus in the Long-term Outcomes of Apical Prolapse Repair
- Open Access
- 26 December 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-18
Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness
The tumor suppressor p53 when undergoes amyloid formation confers several gain-of-function (GOF) activities that affect molecular pathways crucial for tumorigenesis and progression like some of the p53 mutants. Even after successful cancer treatment, metastasis and recurrence can result in poor survival rates. The major cause of recurrence is mainly the remnant cancer cells with stem cell-like properties, which are resistant to any chemotherapy treatment. Several studies have demonstrated the role of p53 mutants in exacerbating cancer stemness properties and epithelial-mesenchymal transition in these remnant cancer cells. Analyzing the amyloid/mutant p53-mediated signaling pathways that trigger metastasis, relapse or chemoresistance may be helpful for the development of novel or improved individualized treatment plans. In this review, we discuss the changes in the metabolic pathways such as mevalonate pathway and different signaling pathways such as TGF-β, PI3K/AKT/mTOR, NF-κB and Wnt due to p53 amyloid formation, or mutation. In addition to this, we have discussed the role of the regulatory microRNAs and lncRNAs linked with the mutant or amyloid p53 in human malignancies. Such changes promote tumor spread, potential recurrence, and stemness. Importantly, this review discusses the cancer therapies that target either mutant or amyloid p53, restore wild-type functions, and exploit the synthetic lethal interactions with mutant p53.
- 26 December 2022
- Published by Springer Nature in Cancer Cell International
- Vol. 22 (1) , 1-18
Open AccessTransition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness
The tumor suppressor p53 when undergoes amyloid formation confers several gain-of-function (GOF) activities that affect molecular pathways crucial for tumorigenesis and progression like some of the p53 mutants. Even after successful cancer treatment, metastasis and recurrence can result in poor survival rates. The major cause of recurrence is mainly the remnant cancer cells with stem cell-like properties, which are resistant to any chemotherapy treatment. Several studies have demonstrated the role of p53 mutants in exacerbating cancer stemness properties and epithelial-mesenchymal transition in these remnant cancer cells. Analyzing the amyloid/mutant p53-mediated signaling pathways that trigger metastasis, relapse or chemoresistance may be helpful for the development of novel or improved individualized treatment plans. In this review, we discuss the changes in the metabolic pathways such as mevalonate pathway and different signaling pathways such as TGF-β, PI3K/AKT/mTOR, NF-κB and Wnt due to p53 amyloid formation, or mutation. In addition to this, we have discussed the role of the regulatory microRNAs and lncRNAs linked with the mutant or amyloid p53 in human malignancies. Such changes promote tumor spread, potential recurrence, and stemness. Importantly, this review discusses the cancer therapies that target either mutant or amyloid p53, restore wild-type functions, and exploit the synthetic lethal interactions with mutant p53.
- 17 December 2022
- Published by Springer Nature in Current Urology Reports
- Vol. 24 (1) , 33-39
Financial Toxicity for Female Patients with Urinary Incontinence
Purpose of Review Urinary incontinence (UI) is a common global condition that has been noted to disproportionately affect women. In this review, the authors present discussion of factors contributing to cost of care and various modalities of cost-effective care for UI for female patients. Recent Findings We found insurance and out-of-pocket (OOP) costs strongly impact of costs for patients. Further, in evaluation of UI, diagnosis can be a costly multi-step process for effective treatment. Treatment can be multimodal, including non-surgical (e.g., pessary, vaginal insert, pelvic floor muscle training, or PFMT), of which PFMT is a cost-effective, effective, and accessible treatment. Pharmacologic management is generally second-line for overactive bladder, but anti-muscarinic drugs and beta-3 agonists are cost-effective depending on willingness-to-pay and the health system in which they are acquired, respectively. Surgical management is considered the most cost-effective treatment as willingness-to-pay increased, with minimally invasive slings being the mainstay. Other relatively novel treatments are also discussed (e.g., EMSELLA) but require further research. Additionally, we discuss systematic barriers in decisions to seek care for urinary incontinence. Summary Urologists are key agents in treating UI for their female patients, and seeking cost-effective options for treatment remains pivotal for quality care.
- 17 December 2022
- Published by Springer Nature in Current Urology Reports
- Vol. 24 (1) , 33-39
Financial Toxicity for Female Patients with Urinary Incontinence
Purpose of Review Urinary incontinence (UI) is a common global condition that has been noted to disproportionately affect women. In this review, the authors present discussion of factors contributing to cost of care and various modalities of cost-effective care for UI for female patients. Recent Findings We found insurance and out-of-pocket (OOP) costs strongly impact of costs for patients. Further, in evaluation of UI, diagnosis can be a costly multi-step process for effective treatment. Treatment can be multimodal, including non-surgical (e.g., pessary, vaginal insert, pelvic floor muscle training, or PFMT), of which PFMT is a cost-effective, effective, and accessible treatment. Pharmacologic management is generally second-line for overactive bladder, but anti-muscarinic drugs and beta-3 agonists are cost-effective depending on willingness-to-pay and the health system in which they are acquired, respectively. Surgical management is considered the most cost-effective treatment as willingness-to-pay increased, with minimally invasive slings being the mainstay. Other relatively novel treatments are also discussed (e.g., EMSELLA) but require further research. Additionally, we discuss systematic barriers in decisions to seek care for urinary incontinence. Summary Urologists are key agents in treating UI for their female patients, and seeking cost-effective options for treatment remains pivotal for quality care.
- 14 March 2022
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 17 (2) , 131-138
Improving Health Literacy Among Underserved Latinas with PFDs
- 14 March 2022
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 17 (2) , 131-138
Improving Health Literacy Among Underserved Latinas with PFDs
- 21 January 2022
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 17 (1) , 48-53
Contemporary Characterization of Urethral Diverticulum
- 21 January 2022
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 17 (1) , 48-53
Contemporary Characterization of Urethral Diverticulum
- Open Access
- 27 October 2021
- Published by Springer Nature in Research Square
The Role of in-Person Support Groups in the Management of Urinary Incontinence in Women from a Mixed-Methods, Randomized Pilot Study
Background To assess the feasibility and acceptability of in-person support groups as a potential intervention for female patients with urinary incontinence. Methods Women over the age of 18 seeking treatment for UI were randomized to standard care with support group participation or to standard care alone. All participants completed validated questionnaires at the beginning and conclusion of the study. Questionnaires were analyzed with repeated measures of ANOVA models in an intention-to-treat manner. Three moderated support group sessions were held and audio recorded. Recordings were transcribed and categorized by frequency into themes using grounded theory methodology. Results A total of 10 control and 8 intervention participants agreed to participate. Seven women attended all three support group sessions and were included in the final analysis. Transcripts from support group sessions observed women identified most with (1) urinary incontinence (UI) as a chronic disease, (2) shame managing UI, and (3) social constraints of toileting. Support participants self-reported appreciation of support group participation and desire for on-going sessions. Analysis of the questionnaires did not demonstrate statistically significant differences. Conclusion Data ascertained from questionnaires was unable to demonstrate a meaningful effect in improved treatment outcomes for control and intervention participants. Grounded theory analysis of transcripts identified four primary themes: (1) appreciation of the support group, (2) UI as a gendered issue, (3) lack of public awareness, and (4) history of negative provider interactions. All support group participants self-reported interest in attending future support group sessions.
- 27 October 2021
- Published by Springer Nature in Research Square
Open AccessThe Role of in-Person Support Groups in the Management of Urinary Incontinence in Women from a Mixed-Methods, Randomized Pilot Study
Background To assess the feasibility and acceptability of in-person support groups as a potential intervention for female patients with urinary incontinence. Methods Women over the age of 18 seeking treatment for UI were randomized to standard care with support group participation or to standard care alone. All participants completed validated questionnaires at the beginning and conclusion of the study. Questionnaires were analyzed with repeated measures of ANOVA models in an intention-to-treat manner. Three moderated support group sessions were held and audio recorded. Recordings were transcribed and categorized by frequency into themes using grounded theory methodology. Results A total of 10 control and 8 intervention participants agreed to participate. Seven women attended all three support group sessions and were included in the final analysis. Transcripts from support group sessions observed women identified most with (1) urinary incontinence (UI) as a chronic disease, (2) shame managing UI, and (3) social constraints of toileting. Support participants self-reported appreciation of support group participation and desire for on-going sessions. Analysis of the questionnaires did not demonstrate statistically significant differences. Conclusion Data ascertained from questionnaires was unable to demonstrate a meaningful effect in improved treatment outcomes for control and intervention participants. Grounded theory analysis of transcripts identified four primary themes: (1) appreciation of the support group, (2) UI as a gendered issue, (3) lack of public awareness, and (4) history of negative provider interactions. All support group participants self-reported interest in attending future support group sessions.
- Open Access
- 2 September 2021
- Published by Elsevier in Urology Case Reports
- Vol. 39, 101829
Refractory eosinophilic cystitis controlled with low-dose cyclosporine therapy: A case report
- 2 September 2021
- Published by Elsevier in Urology Case Reports
- Vol. 39, 101829
Open AccessRefractory eosinophilic cystitis controlled with low-dose cyclosporine therapy: A case report
- Open Access
- 1 September 2018
- Published by Elsevier in Urology Case Reports
- Vol. 20, 62-64
Surgical excision of an acutely symptomatic subpubic cartilaginous cyst in a 70 year old male
- 1 September 2018
- Published by Elsevier in Urology Case Reports
- Vol. 20, 62-64
Open AccessSurgical excision of an acutely symptomatic subpubic cartilaginous cyst in a 70 year old male